HNS was approved by the U.S. Food and Drug Administration in 2014 as a treatment option for patients with moderate to severe OSA who cannot tolerate CPAP.
![](https://www.enttoday.org/wp-content/uploads/2016/09/ENT_0916_pg6a.png)
HNS was approved by the U.S. Food and Drug Administration in 2014 as a treatment option for patients with moderate to severe OSA who cannot tolerate CPAP.
While hypoglossal nerve stimulation can be effective for treating obstructive sleep apnea, factors such as weight and sleep position can decrease its effectiveness
In the absence of infection, lead wire exposure from hypoglossal nerve stimulation implantation can be treated with urgent surgery to reimplant the lead and salvage the device.
HNS procedure may be considered for patients with OSA who fail medical treatment